findmyKOL
Clinical trialNCT01440998CompletedPhase 1Interventional

Dasatinib, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer

SponsorNational Cancer Institute (NCI)Enrollment18Endometrial AdenocarcinomaEndometrial Clear Cell AdenocarcinomaEndometrial Mucinous AdenocarcinomaEndometrial Serous AdenocarcinomaEndometrial Squamous Cell CarcinomaEndometrial Transitional Cell Carcinoma+10 more conditions
View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • M D Anderson Cancer Center

    Houston, Texas, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Carboplatin →Dasatinib →Paclitaxel →
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
20 Sept 2011
Primary completion
31 Dec 2015
Completion
31 Dec 2015
Last update posted
5 Apr 2018
Registered enrollment
18
Registry id
NCT01440998
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.